Approval reported abroad2,3Evidence: Large human trialsMetabolic and weight

Mazdutide1

Also called IBI362, LY33056771

Key takeaway

Mazdutide, also known as IBI362 and LY3305677, is a peptide that activates the receptors for glucagon and GLP-1. It is developed by Innovent Biologics in China and has been studied by Eli Lilly in the United States.5,8,9 Suzhou government reports describe its approval in China in 2025 for long-term weight management and for type 2 diabetes. These are local-government reports, not the national approval decision or full prescribing information.2,3 It is not FDA-approved. FDA says it has warned companies that illegally sold unapproved drugs containing mazdutide falsely labeled as being for research purposes.4 Large randomized trials in China report weight loss and lower blood sugar, with common gastrointestinal side effects.5,6

Mazdutide at a glance

What it isA glucagon and GLP-1 receptor agonist developed by Innovent Biologics (IBI362) and studied by Eli Lilly (LY3305677).5,8,9
FDA statusNot FDA-approved. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels. Suzhou government reports describe approval in China in 2025.2,3,4
Human evidenceLarge randomized trials in China in obesity and type 2 diabetes, and a smaller randomized Phase 2 trial in the United States.5,6,7
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is mazdutide?

Mazdutide is a peptide drug developed in China by Innovent Biologics, which ClinicalTrials.gov lists as the sponsor of trials of IBI362, its development code.5,9

Eli Lilly has sponsored trials of the same drug under the code LY3305677, including a completed Phase 2 trial in the United States.7,8

How is mazdutide thought to work?

Mazdutide is designed to activate the receptors for two hormones, glucagon and GLP-1, which are involved in appetite, blood sugar and energy use.5,7

The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.5,6

What do human studies show?

In GLORY-1, 610 adults in China with overweight or obesity were randomized to mazdutide or placebo. At week 32, average weight change was −10.09% and −12.55% in the two mazdutide groups and +0.45% with placebo. Gastrointestinal events were common.5

In a 28-week trial of 731 adults in China with type 2 diabetes, HbA1c, a measure of long-term blood sugar, fell 0.24 and 0.30 percentage points more with mazdutide than with dulaglutide, and weight fell more. Gastrointestinal events were more frequent with mazdutide.6

In a Phase 2 trial of 179 adults in the United States, estimated weight change at week 32 ranged from −7.3% to −18.1% across mazdutide groups, compared with −0.9% on placebo; 20% of the highest-exposure group stopped because of adverse events.7

What the evidence base contains

  • Large randomized human trial GLORY-1 (NCT05607680): a randomized, double-blind, placebo-controlled Phase 3 trial in 610 adults in China with overweight or obesity, published in The New England Journal of Medicine.5
  • Large randomized human trial A 28-week randomized Phase 3 trial in 731 adults in China with type 2 diabetes that compared mazdutide with dulaglutide, published in Nature.6
  • Controlled human trial A randomized, placebo-controlled Phase 2 trial in 179 adults in the United States with overweight or obesity.7

Evidence-strength label: Large randomized human trials. How this label is assigned

Is mazdutide approved?

Not by FDA. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says it has warned companies that illegally sold unapproved drugs containing mazdutide that were falsely labeled for research purposes or not for human consumption.4

A June 27, 2025 report by the Suzhou Industrial Park market regulator describes Chinese approval of mazdutide for long-term weight management in adults with obesity or overweight.2

A December 19, 2025 Suzhou government report describes approved diabetes and weight-management uses in China.3

These are attributable local-government reports, not China’s national approval decision or complete prescribing information. None of the sources reviewed here reports an approval of mazdutide by FDA or in any jurisdiction outside China.2,3,4

Timeline

  1. Results of the GLORY-1 Phase 3 obesity trial are published in The New England Journal of Medicine.5
  2. A Suzhou Industrial Park regulator report describes Chinese approval of mazdutide for long-term weight management.2
  3. A Suzhou government report describes approved diabetes and weight-management uses in China.3
  4. ClinicalTrials.gov lists Eli Lilly’s Phase 2 trial in the United States as completed.8
  5. FDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date.4

What is still unknown?

The exact terms of the Chinese approval, which the local-government reports do not set out in full.2,3

Its long-term effects on heart, kidney and liver outcomes: the published trials measured weight and blood sugar over 28 to 32 weeks, and further trials, including in heart failure, are registered.5,6,10

What is in mazdutide products sold outside approved channels, which FDA describes as unapproved.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Mazdutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Mazdutide are the records PeptideScanner has selected and published, not every registration or paper about Mazdutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

China: approval reported by local government sources. Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.↗↗↗↗↗

Status sources checked through September 15, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.↗↗↗↗

What the reviewed sources report

Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.↗↗↗↗

What remains unresolved?

  • How do dated regulatory decisions differ by jurisdiction and indication?↗↗↗↗
  • What do full reports establish about missing outcomes, uncommon harms and durability?↗↗↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Mazdutide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.1234

Bottom line from this bounded source set

Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.1234

Reviewed study record

GLORY-1: obesity in China

Design

Randomized, double-blind, placebo-controlled phase 3 trial; NCT05607680.1

Population

610 adults with overweight or obesity participated.1

Outcomes reported

At week 32, intention-to-treat weight changes were −10.09% and −12.55% in active groups versus +0.45% with placebo. Gastrointestinal adverse events were common; adverse-event discontinuation occurred in 1.5%, 0.5% and 1.0%, respectively.1

Limitations

The study concerns its enrolled population and prespecified follow-up. Weight change alone cannot establish cardiovascular benefit or longer-term safety.1

Reviewed study record

Type 2 diabetes: active comparator

Design

Randomized phase 3 comparison with a specified dulaglutide regimen over 28 weeks.2

Population

731 adults in China with type 2 diabetes participated.2

Outcomes reported

Between-group HbA1c differences favored the two mazdutide groups by 0.24 and 0.30 percentage points; reductions in percentage body-weight change were 3.78 and 5.76 percentage points greater than with dulaglutide. Gastrointestinal events were more frequent with mazdutide.2

Limitations

The comparison is specific to the tested regimens and population, not a ranking against all uses of the comparator or other medicines.2

Reviewed study record

Type 2 diabetes: placebo comparison

Design

Randomized, double-blind phase 3 trial with a 24-week primary comparison.3

Population

320 adults in China with type 2 diabetes participated.3

Outcomes reported

HbA1c changes were −1.57 and −2.15 percentage points versus −0.14 with placebo. Gastrointestinal events were common.3

Limitations

The subsequent extension is follow-up of this study, not a separate randomized experiment. Biomarker changes do not establish reduced complications.3

Reviewed study record

US phase 2 obesity trial

Design

Randomized, placebo-controlled phase 2 trial with a week-32 primary endpoint and longer follow-up.4

Population

179 adults with overweight or obesity participated.4

Outcomes reported

The reported hypothetical-estimand weight changes at week 32 were −7.3%, −15.6% and −18.1% versus −0.9%. Adverse events led to discontinuation in 20% of the highest active group.4

Limitations

A hypothetical estimand is not the same as observed outcomes regardless of discontinuation. Population, follow-up and estimand differences prevent direct comparison with GLORY-1.4

Reviewed source set

  1. PubMed · 40421736Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. ↗PubMed PMID 40421736 · EFetch XML reviewed 2026-09-15 · payload SHA-256 3f1a92c9c5640d494093aeaff53a8a7f33e7f6147c381db152785819de20e041
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2411528. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 41407860Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. ↗PubMed PMID 41407860 · EFetch XML reviewed 2026-09-15 · payload SHA-256 96659a8cb3d822294b045d64391e17389e263cdb8d0d5df526d0d74511a52487
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10031-z. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 41407859Mazdutide versus placebo in Chinese adults with type 2 diabetes. ↗PubMed PMID 41407859 · EFetch XML reviewed 2026-09-15 · payload SHA-256 bffc996c2b9b7914594678e16163750d1cd34fad9fce2440e2676f0d296f39b9
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41586-025-10026-w. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  4. PubMed · 42628555Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. ↗PubMed PMID 42628555 · EFetch XML reviewed 2026-09-15 · payload SHA-256 c0802aaae85a624375cf494b71908ffe9c67cce4c3c6a28f704ee56cdf0ac8f6
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2213-8587(26)00160-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

Two phase 2 records concern different programs

NCT04904913 describes a 328-participant Chinese study of IBI362 with a 24-week weight endpoint. NCT06124807 describes a separate 179-participant LY3305677 study with a 32-week primary endpoint and 48-week follow-up. Their results are not interchangeable. NCT04904913 ↗NCT06124807 ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.

The later record includes posted weight results

The LY3305677 registry reports modeled mean weight changes of −7.33%, −15.6% and −18.1% across the three active groups versus −0.85% for placebo at week 32. These are changes from baseline in that study, not placebo-adjusted percentages or a cross-drug ranking. NCT06124807 ↗

Longer follow-up involved attrition

The same registry lists 179 participants starting and 128 completing the study. Its repeated-measures estimates should not be mistaken for measurements observed in every participant at every visit; adverse events were among several discontinuation reasons. NCT06124807 ↗

Result availability differs between the two records

The retrieved Chinese phase 2 record has no posted summary-results section, while the LY3305677 record does. Neither registry entry alone establishes the current authorization status in any jurisdiction. NCT04904913 ↗NCT06124807 ↗

What remains to be checked

  • Reconcile Chinese and international trial families and current jurisdiction-specific regulatory documents.
  • Appraise original publications and analysis plans, including missing-data assumptions and safety outcomes.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Scoped identity/name search for initial human evidence synthesis; other aliases and preclinical, extension and combination reports require separate eligibility decisions.

51 retrieved · 4 included · 0 excluded · 47 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"mazdutide"[Title/Abstract] OR "IBI362"[Title/Abstract] OR "LY3305677"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
  • PubMed reported query warnings: {"outputmessages": [], "phrasesignored": [], "quotedphrasesnotfound": ["\"IBI 362\"[Title/Abstract]"]}

Showing 25 of 51 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42628555 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT06124807.
  2. PubMed 41407860 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT05606913.
  3. PubMed 41407859 — include: Selected human report; abstract and record metadata reviewed. Study families: mazdutide-PMID41407859-registry-linkage-unresolved.
  4. PubMed 40421736 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT05607680.
  5. PubMed 42603384 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42410325 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 42688617 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 42555719 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 42535526 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 42251768 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 42251596 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 42251595 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 42208956 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 42419792 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 41948476 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 41804840 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 41875890 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 41820018 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 41054801 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 41787737 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 41901218 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 41711462 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 41710707 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 41389801 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 41478576 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"MAZDUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:21.705711+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Mazdutide", "IBI362", "LY3305677"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Mazdutide", "IBI362", "LY3305677"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["Mazdutide", "IBI362", "LY3305677"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          45 retrieved · 0 included · 0 excluded · 45 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "Mazdutide" OR "IBI362" OR "LY3305677"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:26:39.795239+00:00 · HTTP 200 · SHA-256 43dd4c6f1608bbea1c97f46d6747dcd93acc78d66b1befced9f46133f2e27b9c.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 25 of 45 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          1. ClinicalTrials.gov NCT05793450 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          2. ClinicalTrials.gov NCT06817356 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          3. ClinicalTrials.gov NCT07255209 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          4. ClinicalTrials.gov NCT06184568 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          5. ClinicalTrials.gov NCT07713992 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          6. ClinicalTrials.gov NCT06937749 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          7. ClinicalTrials.gov NCT07135141 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          8. ClinicalTrials.gov NCT06124807 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          9. ClinicalTrials.gov NCT02972645 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          10. ClinicalTrials.gov NCT04773977 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          11. ClinicalTrials.gov NCT05815680 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          12. ClinicalTrials.gov NCT04904913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          13. ClinicalTrials.gov NCT07797101 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          14. ClinicalTrials.gov NCT04466904 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          15. ClinicalTrials.gov NCT07718126 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          16. ClinicalTrials.gov NCT07517042 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          17. ClinicalTrials.gov NCT07803705 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          18. ClinicalTrials.gov NCT07000955 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          19. ClinicalTrials.gov NCT06931028 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          20. ClinicalTrials.gov NCT07657676 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          21. ClinicalTrials.gov NCT07781150 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          22. ClinicalTrials.gov NCT06884293 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          23. ClinicalTrials.gov NCT07767552 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          24. ClinicalTrials.gov NCT05606913 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          25. ClinicalTrials.gov NCT07809945 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of Mazdutide?

          China: approval reported by local government sources. Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.↗↗↗↗↗

          The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          2
          Source years
          3
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Latest source-dated record

          What changed most recently at a cited source?

          Clinical trials · source date November 12, 2026

          ClinicalTrials.gov record NCT07517042↗Added to PeptideScanner November 14, 2026

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to Mazdutide?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          22Selected dated records
          28Connected citations
          3Populated source years2024–2026
          2/4Record lanes present

          Registered human studies

          Trial composition

          13 of 17 selected trial records include at least one phase value; 13 of 17 include a status value in the retained structured contract.

          31 public history versions connect to 7 of these trial records across 4 submitted years. Open the record-history collection →

          PhasesPhase 2 6Not applicable 4Phase 3 3Phase 4 1
          Status at observationNot yet recruiting 5Recruiting 4Active, not recruiting 2Completed 2

          A phase value is unavailable here for 4 selected records; this is not counted as “no phase.”

          A status value is unavailable here for 4 selected records; this is not counted as a trial status.

          PubMed bibliography

          Publication composition

          0 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Bibliography fields unavailable here for 5 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          0
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          22

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 22 dated records

          Research hub

          Explore the Mazdutide evidence record

          Open all 22 records →
          22Dated records
          2Evidence types
          22Cited public sources
          3Source years

          Change ledger

          Recently changed for Mazdutide

          Open all 25 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          Mazdutide profile

          We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile
          Record added

          ClinicalTrials.gov record NCT06862908

          PeptideScanner retained ClinicalTrials.gov record NCT06862908 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was mazdutide.

          PeptideScanner change date
          November 14, 2026
          Cited source date
          September 22, 2026
          Evidence lane
          Clinical trials
          Record added

          ClinicalTrials.gov record NCT06937749

          PeptideScanner retained ClinicalTrials.gov record NCT06937749 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was mazdutide.

          PeptideScanner change date
          November 14, 2026
          Cited source date
          October 20, 2026
          Evidence lane
          Clinical trials

          Official-source collections

          Source records for Mazdutide

          Open the full research atlas →
          ClinicalTrials.gov16

          31 public history versions across these dated registry records; status labels apply only to each cited observation.

          1. NCT07517042Registry update November 12, 2026 · current at observation
          2. NCT07775846Registry update November 10, 2026 · current at observation
          3. NCT07924553Registry update November 9, 2026 · current at observation
          Explore all selected trial records →Explore all public record history →

          Evidence types

          Coverage by source year

          Selected records span March 7, 2024 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • West China Hospital1
          • Innovent Biologics9
          • U.S. Food and Drug Administration4

          Trial records

          Dated updates connected to this profile · 22

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Clinical trials

            ClinicalTrials.gov record NCT07517042↗

            PeptideScanner retained ClinicalTrials.gov record NCT07517042 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          2. Clinical trials

            ClinicalTrials.gov record NCT07775846↗

            PeptideScanner retained ClinicalTrials.gov record NCT07775846 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          3. Clinical trials

            ClinicalTrials.gov record NCT07924553↗

            PeptideScanner retained ClinicalTrials.gov record NCT07924553 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          4. Clinical trials

            ClinicalTrials.gov record NCT07897305↗

            PeptideScanner retained ClinicalTrials.gov record NCT07897305 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          5. Clinical trials

            ClinicalTrials.gov record NCT06937749↗

            PeptideScanner retained ClinicalTrials.gov record NCT06937749 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          6. Clinical trials

            ClinicalTrials.gov record NCT07843862↗

            PeptideScanner retained ClinicalTrials.gov record NCT07843862 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          7. Clinical trials

            ClinicalTrials.gov record NCT06862908↗

            PeptideScanner retained ClinicalTrials.gov record NCT06862908 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          8. Clinical trials

            ClinicalTrials.gov record NCT07803705↗

            PeptideScanner retained ClinicalTrials.gov record NCT07803705 at 2026-09-09T19:17:17.113Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          9. Clinical trials

            ClinicalTrials.gov record NCT07083154↗

            PeptideScanner retained ClinicalTrials.gov record NCT07083154 at 2026-09-09T19:17:17.091Z. Its registry update date was 2026-09-02, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          10. Literature metadata

            PubMed record PMID 42251596↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42251596 at 2026-08-10T10:49:10.669Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-06-07. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.↗

          11. Clinical trials

            ClinicalTrials.gov record NCT07718126↗

            PeptideScanner retained ClinicalTrials.gov record NCT07718126 at 2026-08-10T18:10:03.957Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was mazdutide.↗

          12. Clinical trials

            Mazdutide living-liver-donor study record posted↗

            ClinicalTrials.gov lists a Mazdutide study that is not yet recruiting sponsored by West China Hospital.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            Pre-hepatectomy Rehabilitation in Living Liver Donors With Mazdutide · record history version 1 · last update posted 2026-07-21 ↗

            ClinicalTrials.gov · Official source · Source checked July 22, 2026

          2. 2
            June 27, 2025 government report of Chinese approval for mazdutide weight management ↗

            Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026

          3. 3
            December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗

            Suzhou Municipal Government · Official source · Source checked September 15, 2026

          4. 4
            FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          5. 5
            Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1, 2025) · PMID 40421736 ↗

            The New England Journal of Medicine · Official source · Source checked November 14, 2026

          6. 6
            Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (2025) · PMID 41407860 ↗

            Nature · Official source · Source checked November 14, 2026

          7. 7
            Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial (2026) · PMID 42628555 ↗

            The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

          8. 8
            ClinicalTrials.gov record NCT06124807 · retained source version 2026-04-21:5c8024d2506081c76bbe43d846c2785e0fea51ea4fcaad5871b2b0dacb114691 ↗

            ClinicalTrials.gov · Official source · Source checked August 14, 2026

          9. 9
            ClinicalTrials.gov record NCT07469800 · retained source version 2026-05-27:81ca4ac5542c9dd986eb9ee84eec93f13dc03f4151273b5eb069ff56c5baf9ac ↗

            ClinicalTrials.gov · Official source · Source checked August 14, 2026

          10. 10
            ClinicalTrials.gov record NCT06862908 · retained source version 2026-09-22:928b8a0878066ce68fb99d71bae27f43671911707e3e4a0bbeabad9a2ee02ea0 ↗

            ClinicalTrials.gov · Official source · Source checked November 14, 2026